Trials / Unknown
UnknownNCT02123732
Role of DbXell in the Treatment of Subjects With Mildly Uncontrolled Type 2 Diabetes Mellitus
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Laniado Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a 2-arm, single-blind, crossover, placebo-controlled clinical study, with 24 weeks of therapy to evaluate the efficacy and safety of DbXell in improving metabolic control in patients with Type 2 Diabetes that is mildly uncontrolled, defined as HbA1c above target but less than 8.0% on their current conventional therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | DbXell | |
| DIETARY_SUPPLEMENT | Placebo |
Timeline
- Start date
- 2014-07-01
- Primary completion
- 2017-02-01
- First posted
- 2014-04-28
- Last updated
- 2017-03-07
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT02123732. Inclusion in this directory is not an endorsement.